Coloplast A/S ((GB:0QBO)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Coloplast A/S is conducting a clinical study titled ‘Feasibility of a Newly Developed Ostomy Prototype’ to address leakage issues faced by individuals with ileostomy. The study aims to test a new leakage measurement device designed to improve the quality of life for stoma patients by reducing leakage problems.
The intervention being tested is a device named CP369, a newly developed ostomy prototype. This device is intended to measure and potentially reduce leakage around stomas, thereby enhancing patient comfort and confidence.
The study is designed as an open-label, single-arm trial, where participants serve as their own controls. There is no masking involved, and the primary purpose is to assess the feasibility of the device.
The study is set to begin on July 25, 2025, with the primary completion and estimated completion dates yet to be announced. The last update was submitted on August 27, 2025, indicating the study is in its initial stages.
This development could positively impact Coloplast’s stock performance by showcasing innovation in addressing common patient concerns, potentially setting the company apart from competitors in the medical device industry.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.